Premium
Low‐dose rabeprazole, amoxicillin and metronidazole triple therapy for the treatment of Helicobacter pylori infection in Chinese patients
Author(s) -
WONG WAI MAN,
HUANG JIAQING,
XIA HARRY HX,
FUNG FIONA MY,
TONG TERESA SM,
CHEUNG KESS L,
HO VICKY YK,
LAI KAM CHUEN,
CHAN CHI KUEN,
CHAN ANNIE OO,
HUI CHEEKIN,
LAM SHIU KUM,
WONG BENJAMIN CY
Publication year - 2005
Publication title -
journal of gastroenterology and hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.214
H-Index - 130
eISSN - 1440-1746
pISSN - 0815-9319
DOI - 10.1111/j.1440-1746.2005.03889.x
Subject(s) - rabeprazole , amoxicillin , metronidazole , helicobacter pylori , medicine , gastroenterology , breath test , urea breath test , population , antibiotics , helicobacter pylori infection , microbiology and biotechnology , biology , environmental health
Background: Rabeprazole in combination with amoxicillin and metronidazole (RAM) has been shown to be an effective second‐line treatment of Helicobacter pylori infection. The effects were compared of 7‐day low‐dose and high dose rabeprazole in RAM for the primary treatment of H. pylori infection in Chinese patients. Methods: Helicobacter pylori ‐positive dyspeptic patients were randomized to receive either (i) rabeprazole 10 mg, amoxicillin 1000 mg and metronidazole 400 mg (RAM‐10) or (ii) high‐dose rabeprazole 20 mg, amoxicillin 1000 mg and metronidazole 400 mg (RAM‐20), each given twice daily for 7 days. Helicobacter pylori eradication was confirmed by 13 C‐urea breath test 5 weeks after stopping medications. Side‐effects of treatments were documented. Results: A total of 120 patients were eligible for analysis. By intention‐to‐treat and per‐protocol analysis, the eradication rates were 83% and 86% in the RAM‐10 group and 75% and 76% in the RAM‐20 group, respectively ( P = 0.26 and P = 0.17). Both regimens were well‐tolerated and compliance was >98% in both groups. Conclusions: Low‐dose rabeprazole in combination with amoxicillin and metronidazole is an effective, economical and well‐tolerated therapy for the treatment of H. pylori infection in Chinese population.